Strategies that target HMGB1 through the use of molecular inhibitors [71] or by inhibiting HMGB1 signaling pathways [72] have been shown to be effective in reducing mortality in sepsis models and altering early cytokine profiles to patterns observed in survivors. The gene discussed is HMGB1; the disease is Sepsis.